On September 12, 2019 Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T cell enhancing therapeutics, reported that it has signed collaborations with worldrenowned oncology research groups at the University of Oxford and the University of Surrey (Press release, Crescendo Biologics, SEP 12, 2019, View Source [SID1234539465]). These collaborations will accelerate the development of CB307, Crescendo’s lead programme for PSMA positive tumours, and its follow-on pipeline of CD137-directed T cell enhancing programmes.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Department of Oncology at the University of Oxford is one of the world’s leading cancer research centres. Dr Kerry Fisher’s group within this department, focuses on deepening our understanding of the tumour microenvironment to develop innovative new therapies for cancer patients.
Professor Hardev Pandha is a clinician scientist and a medical oncologist at the University of Surrey. He is head of the University’s Targeted Cancer Therapy research group, Director of the Surrey Cancer Research Institute and an expert in the management of patients with urological cancers. Professor Pandha leads a highly respected team with key interests in early phase clinical trials with targeted agents and novel therapies in translational settings.
Theodora Harold, CEO of Crescendo Biologics, commented:
Professor Pandha and Dr Fisher each head up world-leading groups-it is a credit to the quality of our science to be able to collaborate with them. Their multidisciplinary and collaborative approaches to oncology research will allow Crescendo to gain a greater understanding of these difficult to treat cancers and support us to deliver first in class, targeted T cell therapies."
Dr Kerry Fisher, Department of Oncology, University of Oxford, commented: "We look forward to working with Crescendo to further explore and understand the mechanisms driving the development of cancers and applying our group’s translational expertise to advance Crescendo’s novel Humabody programmes."
Professor Hardev Pandha, University of Surrey, added:
"We are delighted to be exploring the potential of Crescendo’s novel, targeted, T cell co-stimulatory molecules to deliver therapeutic benefit to patients with high unmet medical need."